Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

NCT07339059 is registered in ClinicalTrials.gov with Bindu R Potugari as lead sponsor.

NCT NCT07339059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07339059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Lead sponsor
Bindu R Potugari
Phase
Phase 2
Overall status
Recruiting
Start date
May 14, 2026
Completion date
December 1, 2029
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer (es-sclc), small cell lung cancer ( sclc )